AU2022261159A1 - Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof - Google Patents

Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof Download PDF

Info

Publication number
AU2022261159A1
AU2022261159A1 AU2022261159A AU2022261159A AU2022261159A1 AU 2022261159 A1 AU2022261159 A1 AU 2022261159A1 AU 2022261159 A AU2022261159 A AU 2022261159A AU 2022261159 A AU2022261159 A AU 2022261159A AU 2022261159 A1 AU2022261159 A1 AU 2022261159A1
Authority
AU
Australia
Prior art keywords
solid form
ray powder
powder diffraction
exhibits
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022261159A
Other languages
English (en)
Inventor
Stephen W. Kaldor
Toufike Kanouni
Andrew PHIMISTER
Jayachandra P. REDDY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of AU2022261159A1 publication Critical patent/AU2022261159A1/en
Assigned to PIERRE FABRE MEDICAMENT reassignment PIERRE FABRE MEDICAMENT Request for Assignment Assignors: KINNATE BIOPHARMA INC.
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2022261159A 2021-04-23 2022-04-21 Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof Pending AU2022261159A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178752P 2021-04-23 2021-04-23
US63/178,752 2021-04-23
PCT/US2022/025815 WO2022226221A1 (en) 2021-04-23 2022-04-21 Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof

Publications (1)

Publication Number Publication Date
AU2022261159A1 true AU2022261159A1 (en) 2023-11-23

Family

ID=83723159

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022261159A Pending AU2022261159A1 (en) 2021-04-23 2022-04-21 Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof

Country Status (11)

Country Link
US (1) US20240208931A1 (https=)
EP (1) EP4326255A4 (https=)
JP (1) JP7825636B2 (https=)
KR (1) KR20240000540A (https=)
CN (1) CN117529313A (https=)
AU (1) AU2022261159A1 (https=)
BR (1) BR112023021916A2 (https=)
CA (1) CA3216258A1 (https=)
IL (1) IL307910A (https=)
MX (1) MX2023012521A (https=)
WO (1) WO2022226221A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7626910B2 (ja) 2019-10-24 2025-02-05 ピエール ファーブル メディカモン Ｒａｆキナーゼの阻害剤
WO2022081469A1 (en) 2020-10-12 2022-04-21 Kinnate Biopharma Inc. Inhibitors of raf kinases
BR112023021913A2 (pt) 2021-04-23 2024-01-16 Kinnate Biopharma Inc Tratamento de câncer com inibidor de raf

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9242969B2 (en) * 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) * 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
KR20210055042A (ko) * 2018-07-31 2021-05-14 오스칸 그룹 홀딩스 엘티디 “고체의 자가-유화 약학 조성물”
WO2020198058A1 (en) * 2019-03-22 2020-10-01 Kinnate Biopharma Inc. Inhibitors of raf kinases
TW202106684A (zh) * 2019-05-03 2021-02-16 美商奇奈特生物製藥公司 Raf激酶抑制劑
JP7626910B2 (ja) * 2019-10-24 2025-02-05 ピエール ファーブル メディカモン Ｒａｆキナーゼの阻害剤

Also Published As

Publication number Publication date
KR20240000540A (ko) 2024-01-02
IL307910A (en) 2023-12-01
JP2024517431A (ja) 2024-04-22
CN117529313A (zh) 2024-02-06
US20240208931A1 (en) 2024-06-27
BR112023021916A2 (pt) 2023-12-19
JP7825636B2 (ja) 2026-03-06
EP4326255A4 (en) 2025-03-12
CA3216258A1 (en) 2022-10-27
TW202309018A (zh) 2023-03-01
WO2022226221A1 (en) 2022-10-27
EP4326255A1 (en) 2024-02-28
MX2023012521A (es) 2023-12-15

Similar Documents

Publication Publication Date Title
US20220370436A1 (en) C-Met Modulator Pharmaceutical Compositions
US20240208931A1 (en) Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof
US10703724B2 (en) Crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation thereof
US20210163457A1 (en) Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof
US10150770B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
TW201720803A (zh) 唾液酸或其鹽或溶劑合物之晶型
CN110621662A (zh) 一种盐的结晶性固体形式、制备工艺和使用方法
WO2014082354A1 (zh) 西达本胺的晶型及其制备方法与应用
WO2022017478A1 (zh) 一种环己烷甲酰胺的新晶型及其制备方法
US20250059170A1 (en) Solid state forms of an fgfr inhibitor
WO2019003249A1 (en) POLYMORPHIC FORMS OF BARICITINIB
CN106279127A (zh) 阿法替尼酸加成盐及其晶型、其制备方法及药物组合物
ES2651689T3 (es) Forma salina de alfa-6-mPEG6-O-hidroxicodona sólida como antagonista opioide y usos de la misma
CN110650960B (zh) Acalabrutinib的新晶型及其制备方法和用途
CN106928218A (zh) 吗啉衍生物的盐及其晶型、其制备方法及药物组合物、用途
TWI922665B (zh) (s)-n-(3-(2-(((r)-1-羥基丙-2-基)胺基)-6-嗎啉基吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯啶-1-甲醯胺及其鹽之固態形式
HK40107041A (zh) 固态形式的(s)-n-(3-(2-(((r)-1-羟基丙-2-基)氨基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-3-(2，2，2-三氟乙基)吡咯烷-1-甲酰胺及其盐
CN113677401A (zh) 作为ERK抑制剂的5,6-二氢-4H-噻吩并[2,3-c]吡咯-4-酮化合物的盐
US20240270733A1 (en) Hydrate form of lazertinib mesylate, preparation method thereof and use thereof
WO2026040323A1 (zh) 一种依鲁替尼单月桂醇硫酸盐、制备方法、应用
WO2025207649A1 (en) Solid state forms of an akt1 inhibitor and salts thereof
WO2017029408A1 (en) Solid state forms of sofosbuvir

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PIERRE FABRE MEDICAMENT

Free format text: FORMER APPLICANT(S): KINNATE BIOPHARMA INC.